当前位置：
X-MOL 学术
›
Dermatol. Ther.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Correction to: Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic Dermatitis
Dermatology and Therapy ( IF 3.5 ) Pub Date : 2024-01-20 , DOI: 10.1007/s13555-023-01076-x Kim Rand 1 , Juan Manuel Ramos-Goñi 1 , Bülent Akmaz 2 , Laia Solé-Feu 3 , José-Carlos Armario-Hita 4
中文翻译：
更正：Lebrikizumab 与 Dupilumab 在中度至重度特应性皮炎中的长期疗效维持和不良事件发生率的匹配调整间接比较
更新日期：2024-01-21
Dermatology and Therapy ( IF 3.5 ) Pub Date : 2024-01-20 , DOI: 10.1007/s13555-023-01076-x Kim Rand 1 , Juan Manuel Ramos-Goñi 1 , Bülent Akmaz 2 , Laia Solé-Feu 3 , José-Carlos Armario-Hita 4
Affiliation
|
中文翻译：
更正：Lebrikizumab 与 Dupilumab 在中度至重度特应性皮炎中的长期疗效维持和不良事件发生率的匹配调整间接比较
京公网安备 11010802027423号